{"id":821450,"date":"2022-09-20T19:06:43","date_gmt":"2022-09-20T17:06:43","guid":{"rendered":"https:\/\/15.161.165.86\/non-categorizzato\/cosette-pharmaceuticals-announces-the-approval-and-launch-of-first-generic-versions-of-tazorac-tazarotene-gel-0-05-and-0-1-with-180-days-competitive-generic-therapy-cgt-exclusivity\/"},"modified":"2022-09-20T19:06:43","modified_gmt":"2022-09-20T17:06:43","slug":"cosette-pharmaceuticals-announces-the-approval-and-launch-of-first-generic-versions-of-tazorac-tazarotene-gel-0-05-and-0-1-with-180-days-competitive-generic-therapy-cgt-exclusivity","status":"publish","type":"post","link":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/cosette-pharmaceuticals-announces-the-approval-and-launch-of-first-generic-versions-of-tazorac-tazarotene-gel-0-05-and-0-1-with-180-days-competitive-generic-therapy-cgt-exclusivity\/","title":{"rendered":"Cosette Pharmaceuticals Announces the Approval and Launch of First Generic Versions of TAZORAC\u00ae (tazarotene) gel, 0.05% and 0.1%, with 180 days Competitive Generic Therapy (CGT) exclusivity"},"content":{"rendered":"BRIDGEWATER, N.J.--(BUSINESS WIRE)--#abreva--Cosette Pharmaceuticals, Inc. (\"Cosette\") announced that the U.S. Food and Drug Administration (FDA) has approved the Abbreviated New Drug Applications (ANDA) for the first generic versions of TAZORAC\u00ae (tazarotene) gel, 0.05% and 0.1%, with 180 days Competitive Generic Therapy (CGT) exclusivity. Cosette has already commenced commercial shipments, triggering the 180 days exclusivity.\n\n\n\nApurva Saraf, President and CEO of Cosette Pharma, stated, \"This approval and immediate launch represents an important milestone in the evolution of Cosette, and reaffirms our commitment to world class R&D and operational excellence. Since we reset and refocused our R&D efforts in mid-2020, we now have sev
Abbonati<\/a> o Accedi<\/a> per leggere il resto di questo contenuto.<\/div><\/div>","protected":false},"excerpt":{"rendered":"

BRIDGEWATER, N.J.–(BUSINESS WIRE)–#abreva–Cosette Pharmaceuticals, Inc. (“Cosette”) announced that the U.S. Food and Drug Administration (FDA) has approved the Abbreviated New Drug Applications (ANDA) for the first generic versions of TAZORAC\u00ae (tazarotene) gel, 0.05% and 0.1%, with 180 days Competitive Generic Therapy (CGT) exclusivity. Cosette has already commenced commercial shipments, triggering the 180 days exclusivity. Apurva […]<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[49625],"tags":[],"settori":[],"slider_categorie_and_home_page":[],"class_list":["post-821450","post","type-post","status-publish","format-standard","hentry","category-private-capital-in-north-america"],"acf":[],"yoast_head":"\nCosette Pharmaceuticals Announces the Approval and Launch of First Generic Versions of TAZORAC\u00ae (tazarotene) gel, 0.05% and 0.1%, with 180 days Competitive Generic Therapy (CGT) exclusivity - BeBeez<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/cosette-pharmaceuticals-announces-the-approval-and-launch-of-first-generic-versions-of-tazorac-tazarotene-gel-0-05-and-0-1-with-180-days-competitive-generic-therapy-cgt-exclusivity\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cosette Pharmaceuticals Announces the Approval and Launch of First Generic Versions of TAZORAC\u00ae (tazarotene) gel, 0.05% and 0.1%, with 180 days Competitive Generic Therapy (CGT) exclusivity - BeBeez\" \/>\n<meta property=\"og:description\" content=\"BRIDGEWATER, N.J.--(BUSINESS WIRE)--#abreva--Cosette Pharmaceuticals, Inc. ("Cosette") announced that the U.S. Food and Drug Administration (FDA) has approved the Abbreviated New Drug Applications (ANDA) for the first generic versions of TAZORAC\u00ae (tazarotene) gel, 0.05% and 0.1%, with 180 days Competitive Generic Therapy (CGT) exclusivity. Cosette has already commenced commercial shipments, triggering the 180 days exclusivity. Apurva […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/cosette-pharmaceuticals-announces-the-approval-and-launch-of-first-generic-versions-of-tazorac-tazarotene-gel-0-05-and-0-1-with-180-days-competitive-generic-therapy-cgt-exclusivity\/\" \/>\n<meta property=\"og:site_name\" content=\"BeBeez\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-20T17:06:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo-x2.png\" \/>\n\t<meta property=\"og:image:width\" content=\"683\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/cosette-pharmaceuticals-announces-the-approval-and-launch-of-first-generic-versions-of-tazorac-tazarotene-gel-0-05-and-0-1-with-180-days-competitive-generic-therapy-cgt-exclusivity\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/cosette-pharmaceuticals-announces-the-approval-and-launch-of-first-generic-versions-of-tazorac-tazarotene-gel-0-05-and-0-1-with-180-days-competitive-generic-therapy-cgt-exclusivity\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Cosette Pharmaceuticals Announces the Approval and Launch of First Generic Versions of TAZORAC\u00ae (tazarotene) gel, 0.05% and 0.1%, with 180 days Competitive Generic Therapy (CGT) exclusivity\",\"datePublished\":\"2022-09-20T17:06:43+00:00\",\"dateModified\":\"2022-09-20T17:06:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/cosette-pharmaceuticals-announces-the-approval-and-launch-of-first-generic-versions-of-tazorac-tazarotene-gel-0-05-and-0-1-with-180-days-competitive-generic-therapy-cgt-exclusivity\/\"},\"wordCount\":299,\"publisher\":{\"@id\":\"https:\/\/15.161.165.86\/#organization\"},\"articleSection\":[\"Private capital in North America\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/cosette-pharmaceuticals-announces-the-approval-and-launch-of-first-generic-versions-of-tazorac-tazarotene-gel-0-05-and-0-1-with-180-days-competitive-generic-therapy-cgt-exclusivity\/\",\"url\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/cosette-pharmaceuticals-announces-the-approval-and-launch-of-first-generic-versions-of-tazorac-tazarotene-gel-0-05-and-0-1-with-180-days-competitive-generic-therapy-cgt-exclusivity\/\",\"name\":\"Cosette Pharmaceuticals Announces the Approval and Launch of First Generic Versions of TAZORAC\u00ae (tazarotene) gel, 0.05% and 0.1%, with 180 days Competitive Generic Therapy (CGT) exclusivity - BeBeez\",\"isPartOf\":{\"@id\":\"https:\/\/15.161.165.86\/#website\"},\"datePublished\":\"2022-09-20T17:06:43+00:00\",\"dateModified\":\"2022-09-20T17:06:43+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/cosette-pharmaceuticals-announces-the-approval-and-launch-of-first-generic-versions-of-tazorac-tazarotene-gel-0-05-and-0-1-with-180-days-competitive-generic-therapy-cgt-exclusivity\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/cosette-pharmaceuticals-announces-the-approval-and-launch-of-first-generic-versions-of-tazorac-tazarotene-gel-0-05-and-0-1-with-180-days-competitive-generic-therapy-cgt-exclusivity\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/cosette-pharmaceuticals-announces-the-approval-and-launch-of-first-generic-versions-of-tazorac-tazarotene-gel-0-05-and-0-1-with-180-days-competitive-generic-therapy-cgt-exclusivity\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/bebeez.it\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cosette Pharmaceuticals Announces the Approval and Launch of First Generic Versions of TAZORAC\u00ae (tazarotene) gel, 0.05% and 0.1%, with 180 days Competitive Generic Therapy (CGT) exclusivity\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/15.161.165.86\/#website\",\"url\":\"https:\/\/15.161.165.86\/\",\"name\":\"BeBeez\",\"description\":\"BeBeez\",\"publisher\":{\"@id\":\"https:\/\/15.161.165.86\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/15.161.165.86\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/15.161.165.86\/#organization\",\"name\":\"BeBeez\",\"url\":\"https:\/\/15.161.165.86\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png\",\"contentUrl\":\"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png\",\"width\":309,\"height\":122,\"caption\":\"BeBeez\"},\"image\":{\"@id\":\"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cosette Pharmaceuticals Announces the Approval and Launch of First Generic Versions of TAZORAC\u00ae (tazarotene) gel, 0.05% and 0.1%, with 180 days Competitive Generic Therapy (CGT) exclusivity - BeBeez","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/cosette-pharmaceuticals-announces-the-approval-and-launch-of-first-generic-versions-of-tazorac-tazarotene-gel-0-05-and-0-1-with-180-days-competitive-generic-therapy-cgt-exclusivity\/","og_locale":"en_US","og_type":"article","og_title":"Cosette Pharmaceuticals Announces the Approval and Launch of First Generic Versions of TAZORAC\u00ae (tazarotene) gel, 0.05% and 0.1%, with 180 days Competitive Generic Therapy (CGT) exclusivity - BeBeez","og_description":"BRIDGEWATER, N.J.--(BUSINESS WIRE)--#abreva--Cosette Pharmaceuticals, Inc. (\"Cosette\") announced that the U.S. Food and Drug Administration (FDA) has approved the Abbreviated New Drug Applications (ANDA) for the first generic versions of TAZORAC\u00ae (tazarotene) gel, 0.05% and 0.1%, with 180 days Competitive Generic Therapy (CGT) exclusivity. Cosette has already commenced commercial shipments, triggering the 180 days exclusivity. Apurva […]","og_url":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/cosette-pharmaceuticals-announces-the-approval-and-launch-of-first-generic-versions-of-tazorac-tazarotene-gel-0-05-and-0-1-with-180-days-competitive-generic-therapy-cgt-exclusivity\/","og_site_name":"BeBeez","article_published_time":"2022-09-20T17:06:43+00:00","og_image":[{"width":683,"height":242,"url":"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo-x2.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/cosette-pharmaceuticals-announces-the-approval-and-launch-of-first-generic-versions-of-tazorac-tazarotene-gel-0-05-and-0-1-with-180-days-competitive-generic-therapy-cgt-exclusivity\/#article","isPartOf":{"@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/cosette-pharmaceuticals-announces-the-approval-and-launch-of-first-generic-versions-of-tazorac-tazarotene-gel-0-05-and-0-1-with-180-days-competitive-generic-therapy-cgt-exclusivity\/"},"author":{"name":"","@id":""},"headline":"Cosette Pharmaceuticals Announces the Approval and Launch of First Generic Versions of TAZORAC\u00ae (tazarotene) gel, 0.05% and 0.1%, with 180 days Competitive Generic Therapy (CGT) exclusivity","datePublished":"2022-09-20T17:06:43+00:00","dateModified":"2022-09-20T17:06:43+00:00","mainEntityOfPage":{"@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/cosette-pharmaceuticals-announces-the-approval-and-launch-of-first-generic-versions-of-tazorac-tazarotene-gel-0-05-and-0-1-with-180-days-competitive-generic-therapy-cgt-exclusivity\/"},"wordCount":299,"publisher":{"@id":"https:\/\/15.161.165.86\/#organization"},"articleSection":["Private capital in North America"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/cosette-pharmaceuticals-announces-the-approval-and-launch-of-first-generic-versions-of-tazorac-tazarotene-gel-0-05-and-0-1-with-180-days-competitive-generic-therapy-cgt-exclusivity\/","url":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/cosette-pharmaceuticals-announces-the-approval-and-launch-of-first-generic-versions-of-tazorac-tazarotene-gel-0-05-and-0-1-with-180-days-competitive-generic-therapy-cgt-exclusivity\/","name":"Cosette Pharmaceuticals Announces the Approval and Launch of First Generic Versions of TAZORAC\u00ae (tazarotene) gel, 0.05% and 0.1%, with 180 days Competitive Generic Therapy (CGT) exclusivity - BeBeez","isPartOf":{"@id":"https:\/\/15.161.165.86\/#website"},"datePublished":"2022-09-20T17:06:43+00:00","dateModified":"2022-09-20T17:06:43+00:00","breadcrumb":{"@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/cosette-pharmaceuticals-announces-the-approval-and-launch-of-first-generic-versions-of-tazorac-tazarotene-gel-0-05-and-0-1-with-180-days-competitive-generic-therapy-cgt-exclusivity\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bebeez.it\/en\/private-capital-in-north-america\/cosette-pharmaceuticals-announces-the-approval-and-launch-of-first-generic-versions-of-tazorac-tazarotene-gel-0-05-and-0-1-with-180-days-competitive-generic-therapy-cgt-exclusivity\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/bebeez.it\/en\/private-capital-in-north-america\/cosette-pharmaceuticals-announces-the-approval-and-launch-of-first-generic-versions-of-tazorac-tazarotene-gel-0-05-and-0-1-with-180-days-competitive-generic-therapy-cgt-exclusivity\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/bebeez.it\/en\/"},{"@type":"ListItem","position":2,"name":"Cosette Pharmaceuticals Announces the Approval and Launch of First Generic Versions of TAZORAC\u00ae (tazarotene) gel, 0.05% and 0.1%, with 180 days Competitive Generic Therapy (CGT) exclusivity"}]},{"@type":"WebSite","@id":"https:\/\/15.161.165.86\/#website","url":"https:\/\/15.161.165.86\/","name":"BeBeez","description":"BeBeez","publisher":{"@id":"https:\/\/15.161.165.86\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/15.161.165.86\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/15.161.165.86\/#organization","name":"BeBeez","url":"https:\/\/15.161.165.86\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/","url":"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png","contentUrl":"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png","width":309,"height":122,"caption":"BeBeez"},"image":{"@id":"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts\/821450","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/comments?post=821450"}],"version-history":[{"count":0,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts\/821450\/revisions"}],"wp:attachment":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/media?parent=821450"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/categories?post=821450"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/tags?post=821450"},{"taxonomy":"settori","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/settori?post=821450"},{"taxonomy":"slider_categorie_and_home_page","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/slider_categorie_and_home_page?post=821450"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}